# AstraZeneca’s Tagrisso approved in EU in early lung cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-tagrisso-approved-in-eu-in-early-lung-cancer/412993871
- Published: 2021-05-28T07:23:13+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Tagrisso_ (osimertinib) has been approved in the European Union (EU) for the adjuvant
treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth 
factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete
tumour resection with curative intent. _Tagrisso_ is indicated for EGFRm patients
whose tumours have exon 19 deletions or exon 21 (L858R) mutations.

The approval by the European Commission was based on positive results from the ADAURA
Phase III trial in which _Tagrisso_ demonstrated a statistically significant and
clinically meaningful improvement in disease-free survival (DFS) in the primary 
analysis population of patients with Stage II and IIIA EGFRm NSCLC. The trial also
showed a statistically significant and clinically meaningful improvement in DFS 
for _Tagrisso_ in the overall trial population, a key secondary endpoint.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have
surgery with curative intent, recurrence is still common in early-stage disease.
Historically, nearly half of patients diagnosed in Stage IB, and over three quarters
of patients diagnosed in Stage IIIA, have experienced disease recurrence within 
five years.^(1-3) About a fifth of the world’s lung cancer patients are in the EU
and among those with NSCLC, approximately 15% have tumours with an EGFR mutation.
^(4-6)

> **Margarita Majem, MD, PhD, Department of Medical Oncology, Hospital de la Santa
> Creu i Sant Pau, Spain, said**: “In the early stages of lung cancer, where tumour
> resection is possible but recurrence is far too common, adjuvant _Tagrisso_ has
> shown an unprecedented disease-free survival benefit for patients with EGFR mutations.
> I expect this approval will change clinical practice in the EU, as it heightens
> the critical importance of EGFR mutation testing across all stages of lung cancer
> to ensure as many patients as possible can benefit from targeted medicines like
> _Tagrisso._“

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said**: “
> We know the earlier a patient’s cancer is detected and treated, the greater chance
> they may have of being cured, which is why this approval is significant. For the
> first time, patients in the EU with EGFR-mutated lung cancer have a targeted, 
> biomarker-driven treatment option available in the early stages of their disease
> that can help them live cancer-free longer.”

In the ADAURA trial, adjuvant treatment with _Tagrisso_ reduced the risk of disease
recurrence or death by 83% in patients with Stage II and IIIA disease (hazard ratio[
HR] 0.17; 99.06% confidence interval [CI] 0.11-0.26; p<0.001) and by 80% in the 
overall trial population of patients with Stage IB-IIIA disease (HR 0.20; 99.12%
CI 0.14-0.30; p<0.001).

Consistent DFS results were seen regardless of prior adjuvant chemotherapy use and
across all prespecified subgroups. The safety and tolerability of _Tagrisso_ in 
this trial was consistent with previous trials in the metastatic setting. The ADAURA
results were published in The New England Journal of Medicine.

_Tagrisso _is now approved to treat early-stage lung cancer in more than fifty countries,
including in the US and China, and additional global regulatory reviews are ongoing.
_Tagrisso_ is also approved for the 1st-line treatment of patients with locally 
advanced or metastatic EGFRm NSCLC and for the treatment of locally advanced or 
metastatic EGFR T790M mutation-positive NSCLC in the EU, the US, Japan, China and
many other countries.

**Lung cancer**

Lung cancer is the leading cause of cancer death among men and women, accounting
for about one-fifth of all cancer deaths.^(4) Lung cancer is broadly split into 
NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.^(7 )The majority
of NSCLC patients are diagnosed with advanced disease while approximately 25-30%
present with resectable disease at diagnosis.^(1-2) Early-stage lung cancer diagnoses
are often only made when the cancer is found on imaging for an unrelated condition.
^(8-9)

For patients with resectable tumours, the majority of patients eventually develop
recurrence despite complete tumour resection and adjuvant chemotherapy.^(3)

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients
in Asia have EGFRm NSCLC.^(10-12) These patients are particularly sensitive to treatment
with an EGFR-tyrosine kinase inhibitor (TKI) which blocks the cell-signalling pathways
that drive the growth of tumour cells.^(13)

**ADAURA**

ADAURA is a randomised, double-blind, global, placebo-controlled Phase III trial
in the adjuvant treatment of 682 patients with Stage IB, II and IIIA EGFRm NSCLC
following complete tumour resection and adjuvant chemotherapy as indicated. Patients
were treated with _Tagrisso_ 80mg once-daily oral tablets or placebo for three years
or until disease recurrence.

The trial enrolled patients in more than 200 centres across more than 20 countries,
including the US, in Europe, South America, Asia and the Middle East. The primary
endpoint was DFS in Stage II and IIIA patients and a key secondary endpoint was 
DFS in Stage IB, II and IIIA patients.

The data readout was originally anticipated in 2022. In April 2020, an Independent
Data Monitoring Committee recommended for the trial to be unblinded two years early
based on a determination of overwhelming efficacy. Treating physicians and patients
continue to participate and remain blinded to treatment. The trial will continue
to assess overall survival.

**_Tagrisso_**

_Tagrisso_ (osimertinib) is a third-generation, irreversible EGFR TKI with clinical
activity against central nervous system metastases. _Tagrisso_ (40mg and 80mg once-
daily oral tablets) has been used to treat more than 250,000 patients across indications
worldwide and AstraZeneca continues to explore _Tagrisso_ as a treatment for patients
across multiple stages of EGFRm NSCLC.

In Phase III trials, _Tagrisso_ is being tested in the neoadjuvant resectable setting(
NeoADAURA), in the Stage III locally advanced unresectable setting (LAURA) and, 
in combination with chemotherapy, in the Stage III locally advanced or Stage IV 
metastatic settings (FLAURA2). AstraZeneca is also researching ways to address tumour
mechanisms of resistance through the SAVANNAH and ORCHARD Phase II trials, which
test _Tagrisso_ given concomitantly with savolitinib, an oral, potent and highly
selective MET TKI, as well as other potential new medicines.

Share on:
